Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.42 |
| ▸ | NPY4R | P50391 | 7/20 | 0.42 |
| ▸ | NPY1R | P25929 | 5/20 | 0.42 |
| ▸ | CTSD | P07339 | 3/20 | 0.42 |
| ▸ | NPY2R | P49146 | 3/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | TFPI | P10646 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22687904 | 0.94 | NPY4R (0.41) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL30525297 | 0.91 | NPY4R (0.43) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL30272511 | 0.91 | NPY4R (0.43) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL31206359 | 0.90 | NPY4R (0.46) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL5508023 | 0.89 | BACE1 (0.48) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL30945400 | 0.88 | NPY4R (0.51) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL1527412 | 0.88 | NPY4R (0.51) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL30945410 | 0.88 | NPY4R (0.51) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL1527410 | 0.88 | NPY4R (0.51) | BACE1NPY4RNPY1RCTSDNPY2R | |
| SCHEMBL30148447 | 0.88 | NPY4R (0.51) | BACE1NPY4RNPY1RCTSDNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275357-A1 | CAPSULE PROTEIN AND MULTIMERIC COMPLEX COMPOSITION THEREOF, AND PHARMACEUTICAL COMPOSITION USING SAME | UNIVERSITY PUBLIC CORPORATION OSAKA (JP) | 2022-09-01 | — | — | US | disclosed |
| EP-3973788-A1 | CAPSULE PROTEIN AND MULTIMERIC COMPLEX COMPOSITION THEREOF, AND PHARMACEUTICAL COMPOSITION USING SAME | University Public Corporation Osaka (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275357-A1 | CAPSULE PROTEIN AND MULTIMERIC COMPLEX COMPOSITION THEREOF, AND PHARMACEUTICAL COMPOSITION USING SAME | HPGDS, ESD, GC | BACE1 4445/4885NPY4R 3658/4885NPY1R 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.